Company Genmab Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,976 DKK | +62.41% | +4.14% | +14.24% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Business Summary
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sales per Business
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Therapeutics
100.0
%
| 14,595 | 100.0 % | 16,474 | 100.0 % | +12.87% |
Sales per region
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Denmark
97.4
%
| 14,595 | 100.0 % | 16,053 | 97.4 % | +9.99% |
United States
2.3
%
| 0 | 0.0 % | 380 | 2.3 % | - |
Japan
0.2
%
| 0 | 0.0 % | 41 | 0.2 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Tahamtan Ahmadi
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Marisol Peron
IRO | Public Communications Contact | - | 19-03-10 |
Human Resources Officer | 46 | - | |
Judith Klimovsky
PRN | Corporate Officer/Principal | 67 | 17-02-08 |
Martine van Vugt
PRN | Corporate Officer/Principal | 71 | 00-12-31 |
General Counsel | 63 | 01-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
Director/Board Member | 59 | 22-03-28 | |
Director/Board Member | 57 | 14-12-31 | |
Director/Board Member | 73 | 14-12-31 | |
Director/Board Member | 51 | 19-03-28 | |
Martin Schultz
BRD | Director/Board Member | 49 | 21-12-31 |
Director/Board Member | 50 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 66,122,964 | 65,373,793 ( 98.87 %) | 744,170 ( 1.125 %) | 98.87 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GENMAB A/S 1.71% | 1,129,976 | 1.71% | 341,622,175 $ |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.25% | 21.66B | |
-18.35% | 20.77B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B | |
-21.69% | 8.57B |
- Stock Market
- Equities
- GMAB Stock
- Stock
- Company Genmab